Literature DB >> 23493083

Animal models for metabolic, neuromuscular and ophthalmological rare diseases.

Guillaume Vaquer1, Frida Rivière, Maria Mavris, Fabrizia Bignami, Jordi Llinares-Garcia, Kerstin Westermark, Bruno Sepodes.   

Abstract

Animal models are important tools in the discovery and development of treatments for rare diseases, particularly given the small populations of patients in which to evaluate therapeutic candidates. Here, we provide a compilation of mammalian animal models for metabolic, neuromuscular and ophthalmological orphan-designated conditions based on information gathered by the European Medicines Agency's Committee for Orphan Medicinal Products (COMP) since its establishment in 2000, as well as from a review of the literature. We discuss the predictive value of the models and their advantages and limitations with the aim of highlighting those that are appropriate for the preclinical evaluation of novel therapies, thereby facilitating further drug development for rare diseases.

Entities:  

Mesh:

Year:  2013        PMID: 23493083     DOI: 10.1038/nrd3831

Source DB:  PubMed          Journal:  Nat Rev Drug Discov        ISSN: 1474-1776            Impact factor:   84.694


  144 in total

Review 1.  Practical aspects of experimental design in animal research.

Authors:  Paula D Johnson; David G Besselsen
Journal:  ILAR J       Date:  2002

2.  Retinal degeneration 12 (rd12): a new, spontaneously arising mouse model for human Leber congenital amaurosis (LCA).

Authors:  Ji-Jing Pang; Bo Chang; Norman L Hawes; Ronald E Hurd; Muriel T Davisson; Jie Li; Syed M Noorwez; Ritu Malhotra; J Hugh McDowell; Shalesh Kaushal; William W Hauswirth; Steven Nusinowitz; Debra A Thompson; John R Heckenlively
Journal:  Mol Vis       Date:  2005-02-28       Impact factor: 2.367

3.  A peptide composed of tandem analogs of two myasthenogenic T cell epitopes interferes with specific autoimmune responses.

Authors:  Y Katz-Levy; M Paas-Rozner; S Kirshner; M Dayan; E Zisman; M Fridkin; I Wirguin; M Sela; E Mozes
Journal:  Proc Natl Acad Sci U S A       Date:  1997-04-01       Impact factor: 11.205

Review 4.  Knock-in mouse models of Huntington's disease.

Authors:  Liliana B Menalled
Journal:  NeuroRx       Date:  2005-07

5.  Administration of a peptide inhibitor of alpha4-integrin inhibits the development of experimental autoimmune uveitis.

Authors:  Andrea P Martín; Luciana Vieira de Moraes; Carlos E Tadokoro; Alessandra G Commodaro; Enrique Urrets-Zavalia; Gabriel A Rabinovich; Julio Urrets-Zavalia; Luiz V Rizzo; Horacio M Serra
Journal:  Invest Ophthalmol Vis Sci       Date:  2005-06       Impact factor: 4.799

Review 6.  Mouse models of experimental autoimmune uveitis.

Authors:  Rachel R Caspi; Phyllis B Silver; Dror Luger; Jun Tang; Lizette M Cortes; Giuseppina Pennesi; Mary J Mattapallil; Chi-Chao Chan
Journal:  Ophthalmic Res       Date:  2008-04-18       Impact factor: 2.892

Review 7.  Autoimmune disorders of the neuromuscular junction.

Authors:  Bethan Lang; Angela Vincent
Journal:  Curr Opin Pharmacol       Date:  2009-05-08       Impact factor: 5.547

Review 8.  ALS2/alsin knockout mice and motor neuron diseases.

Authors:  Huaibin Cai; Hoon Shim; Chen Lai; Chengsong Xie; Xian Lin; Wan Jou Yang; Jayanth Chandran
Journal:  Neurodegener Dis       Date:  2008-08-20       Impact factor: 2.977

9.  Oxygen-induced retinopathy in the newborn rat: effects of hyperbarism and topical administration of timolol maleate.

Authors:  B Ricci; G Minicucci; A Manfredi; A Santo
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  1995-04       Impact factor: 3.117

10.  Progressive muscular dystrophy in alpha-sarcoglycan-deficient mice.

Authors:  F Duclos; V Straub; S A Moore; D P Venzke; R F Hrstka; R H Crosbie; M Durbeej; C S Lebakken; A J Ettinger; J van der Meulen; K H Holt; L E Lim; J R Sanes; B L Davidson; J A Faulkner; R Williamson; K P Campbell
Journal:  J Cell Biol       Date:  1998-09-21       Impact factor: 10.539

View more
  18 in total

Review 1.  Drug discovery and development for rare genetic disorders.

Authors:  Wei Sun; Wei Zheng; Anton Simeonov
Journal:  Am J Med Genet A       Date:  2017-07-21       Impact factor: 2.802

2.  Isolation and Proteomic Analysis of Mouse Serum Small Extracellular Vesicles for Individual Subject Analysis.

Authors:  Federica Anastasi; Marialaura Dilillo; Davide Pellegrini; Liam A McDonnell
Journal:  Methods Mol Biol       Date:  2022

Review 3.  Disease models for the development of therapies for lysosomal storage diseases.

Authors:  Miao Xu; Omid Motabar; Marc Ferrer; Juan J Marugan; Wei Zheng; Elizabeth A Ottinger
Journal:  Ann N Y Acad Sci       Date:  2016-05-04       Impact factor: 5.691

4.  Heat shock protein-based therapy as a potential candidate for treating the sphingolipidoses.

Authors:  Thomas Kirkegaard; James Gray; David A Priestman; Kerri-Lee Wallom; Jennifer Atkins; Ole Dines Olsen; Alexander Klein; Svetlana Drndarski; Nikolaj H T Petersen; Linda Ingemann; David A Smith; Lauren Morris; Claus Bornæs; Signe Humle Jørgensen; Ian Williams; Anders Hinsby; Christoph Arenz; David Begley; Marja Jäättelä; Frances M Platt
Journal:  Sci Transl Med       Date:  2016-09-07       Impact factor: 17.956

5.  Advances in the Treatment of Neuronal Ceroid Lipofuscinosis.

Authors:  Jonathan B Rosenberg; Alvin Chen; Stephen M Kaminsky; Ronald G Crystal; Dolan Sondhi
Journal:  Expert Opin Orphan Drugs       Date:  2019-11-27       Impact factor: 0.694

6.  Establishing medical plausibility in the context of orphan medicines designation in the European Union.

Authors:  Stelios Tsigkos; Segundo Mariz; Jordi Llinares; Laura Fregonese; Stiina Aarum; Frauke Naumann-Winter; Naumann-Winter Frauke; Kerstin Westermark; Bruno Sepodes
Journal:  Orphanet J Rare Dis       Date:  2014-12-05       Impact factor: 4.123

7.  Integrative Systems Biology Investigation of Fabry Disease.

Authors:  Marco Fernandes; Holger Husi
Journal:  Diseases       Date:  2016-11-15

8.  Catheterization of the gallbladder: A novel mouse model of severe acute cholangitis.

Authors:  Jian-Hua Yu; Hai-Jun Tang; Wei-Guang Zhang; Zhi-Yang Zhu; Xin-Xian Ruan; Bao-Chun Lu
Journal:  World J Gastroenterol       Date:  2017-03-14       Impact factor: 5.742

Review 9.  Regulatory Standards in Orphan Medicinal Product Designation in the EU.

Authors:  Stelios Tsigkos; Segundo Mariz; Maria Elzbieta Sheean; Kristina Larsson; Armando Magrelli; Violeta Stoyanova-Beninska
Journal:  Front Med (Lausanne)       Date:  2021-06-25

10.  Drosophila as a starting point for developing therapeutics for the rare disease Duchenne Muscular Dystrophy.

Authors:  Mario Pantoja; Hannele Ruohola-Baker
Journal:  Rare Dis       Date:  2013-05-10
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.